Cytomedix, Inc. (CMXI.OB)
()
 
 

Overview

Cytomedix is a biotechnology company that develops, sells, and licenses regenerative biological therapies, to primarily address the areas of wound care, inflammation, and angiogenesis. The Company currently markets the AutoloGel™ System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for separation of whole blood into red cells, platelet poor plasma and platelet rich plasma ("PRP") in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from platelet poor plasma. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound market with its products. Cytomedix is also ...


Contact Information

416 Hungerford Drive
Suite 330
Rockville, MD 20850

tel: 240-499-2680
fax: 240-499-2690
http://www.cytomedix.com/

,  



Investor Relations



tel:
fax:
e-mail: nvestorrelations@cytomedix.com




Stock

Exchange: OTCBB
Industry: Biotechnology Research &/or Development
Market Cap: $23M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.